Bioorganic and Medicinal Chemistry p. 3999 - 4008 (2010)
Update date:2022-08-04
Topics:
Crespan, Emmanuele
Radi, Marco
Zanoli, Samantha
Schenone, Silvia
Botta, Maurizio
Maga, Giovanni
The tyrosine kinase Src and its close homolog Abl, both play important roles in chronic myelogenous leukemia (CML) progression and Imatinib resistance. No clinically approved inhibitors of the drug-resistant AblT315I exist to date. Here, we present a thorough kinetic analysis of two potent dual Src-Abl inhibitors towards wild type Src and Abl, and the AblT315I mutant. Our results show that the most potent compound BO1 shows only a modest loss of potency (fourfold) towards the AblT315I mutant in vitro and was an ATP-competitive inhibitor of wild type Abl but it acted as a non-competitive inhibitor in the case of AblT315I.
View MoreShenzhen HwaGen Pharmaceutical Co., Ltd
website:http://www.rafflespt.com
Contact:+86-752-5538396
Address:Guangdong Huizhou China
Zibo Jujin Chemical Industry Co., Ltd.(Dongming Jujin Chemical Industry Co., Ltd. )
Contact:+86-533-2975022
Address:No.99 Shanquan Road, Zhangdian District
Xiamen Hisunny Chemical Co.,Ltd
website:http://www.hisunnychem.com
Contact:+86-592-3327115
Address:Unit 603,No.879,Xiahe Road,Meixin Building,Xiamen,China
Contact:+86-571-86025531 / 86024803
Address:1218-24 Guangyin Mansion,42 Fengqi East Road
Yangling Ciyuan biotech Co., Ltd.
Contact:86-15802970736
Address:2-1804, International Park Mansion, No.2, South Fengdeng Road, Lianhu District
Doi:10.1016/j.saa.2019.117694
(2020)Doi:10.1039/c5dt04723d
(2016)Doi:10.1055/s-0029-1219813
(2010)Doi:10.1002/ejoc.201000140
(2010)Doi:10.1002/jhet.635
(2011)Doi:10.1021/jo00286a021
(1989)